A container (200) for containing a coupling medium for transdermal delivery of a medicament and a transducer unit (100) for use with the container (200) are disclosed. The transducer unit (100) has a transducer (108) with an output face (110), and the container comprises a chamber (214) for receiving the coupling medium and a contact surface (212) for contacting the output face (110) of the transducer (108). The container (200) is attachable to the transducer unit (100) and is arranged such that, upon attachment of the container (200) to the transducer unit (100), an acoustic coupling for ultrasound transmission is formed between the output face (110) of the transducer (108) and the contact surface (212).

A system for cosmetically treating a patient's skin or body with one or more EMS coils and/or RF electrodes mounted on a planar holder; a hydrogel containing gel pad, the gel pad being positionable between the holder and the skin tissue; wherein the gel pad being of a material that is biocompatible and conducts RF and/or EMS energy when EMS energy is applied from the one or more EMS coils; a programmable controller to activate the one or more EMS coils; the programmable controller, after the planar holder is applied to the skin tissue, being configured to activate one or more of the plurality of EMS coils to provide treatment in the form of stimulation to the skin tissue.

The present invention relates to a needle-free injector using pulsed shock waves, the needle-free injector comprising: a power unit generating pulsed power; a pulsed shock wave generating unit which receives the pulsed power and generates pulsed shock waves; an upper housing in which a liquid and the pulsed shock wave generating unit are disposed; a lower housing which is connected to the upper housing, and in which a drug is disposed; a shock wave transmission unit which is provided between the upper housing and the lower housing to separate the upper housing and the lower housing; and an injection unit which is disposed in the lower housing and inject the drug.

A benefit agent delivery system can deliver benefit agents on demand. The benefit agent delivery system comprises a first electrode layer, a microcell layer comprising a plurality of microcells, and a porous second electrode layer. Each of the plurality of microcells are filled with a liquid mixture comprising reverse micelles in a hydrophobic liquid that are formed from a polar liquid, a surfactant or stabilizing particles, and a benefit agent. Application of an electric field across a microcell layer causes an increase in the rate of release of the benefit agent of the microcell through the porous second electrode layer.

Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.

An electrode array for use with an electroporation device includes a support member having a top surface and a bottom surface and defines a plurality of injection channels extending from the top surface to the bottom surface. A plurality of needle electrodes are coupled to the support member, such that distal ends of the plurality of needle electrodes extend to a needle depth below the bottom surface. The plurality of needle electrodes are arranged in a matrix pattern having rows of the needle electrodes and columns of the needle electrodes disposed along the support member. The plurality of injection channels are dispersed within the matrix pattern.

A laser irradiation device for performing treatment on human skin includes a casing that includes a grip part and a barrel part; a laser oscillator that is accommodated in the casing and configured to generate a laser beam to be irradiated through the barrel part; a contact sensor unit that includes electrodes exposed at the end of the barrel part and a contact sensing unit configured to sense an electric current flowing through the electrodes; and a skin treatment unit that is detachably connected to the barrel part and is operated based on electric signals transmitted through the electrodes of the contact sensor unit.

A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.

A method and an system for vaccinating a mammalian subject. The method includes the steps of: arranging a source of electromagnetic radiation proximate to a target zone of skin of the mammalian subject; controlling the source of electromagnetic radiation to deliver a dose of electromagnetic radiation to the target zone determined to create one or more thermally-denatured zones in the target zone; and intradermally injecting a vaccine within the target zone to vaccinate the mammalian subject. The system for vaccinating a subject may include an electromagnetic radiation source configured to be arranged proximate to a target zone on an exterior of the subject; a user control configured to selectively cause the electromagnetic radiation source to deliver a dose of electromagnetic radiation toward the target zone to create one or more thermally-denatured zones in the target zone; and a vaccine-delivery system configured to deliver a vaccine to the target zone.

A device for treating human keratinous material, in particular with the aid of an electric current. The device includes a reservoir containing a composition, in particular cosmetic or dermatological, to be applied to the keratinous material, and an end fitting for the application of the composition contained in the reservoir, the end fitting comprising a plurality of application members and a distributor. The distributor includes at least one storage cavity for the composition and supply orifices to conduct the composition from the storage cavity or cavities to the application members, and the distributor being configured so that the flow rate of the composition arriving at the application members is identical to within 20% for at least two application members, better for each application member.